These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 18380910)
21. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448 [TBL] [Abstract][Full Text] [Related]
22. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Pazianas M; Abrahamsen B; Wang Y; Russell RG Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012 [TBL] [Abstract][Full Text] [Related]
23. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365 [TBL] [Abstract][Full Text] [Related]
24. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. Bae SJ; Kim BJ; Lim KH; Lee SH; Kim HK; Kim GS; Koh JM J Bone Miner Metab; 2012 Sep; 30(5):588-95. PubMed ID: 22610063 [TBL] [Abstract][Full Text] [Related]
27. Factors contributing to compliance with osteoporosis medication. Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234 [TBL] [Abstract][Full Text] [Related]
28. A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women. Yates J Osteoporos Int; 2013 Jan; 24(1):253-62. PubMed ID: 23100120 [TBL] [Abstract][Full Text] [Related]
29. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [TBL] [Abstract][Full Text] [Related]
30. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Rackoff PJ; Sebba A Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341 [TBL] [Abstract][Full Text] [Related]
31. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579 [TBL] [Abstract][Full Text] [Related]
32. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689 [TBL] [Abstract][Full Text] [Related]
33. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE; J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680 [TBL] [Abstract][Full Text] [Related]
35. Adherence to Daily, Weekly, and Monthly Dosing Regimens of Bisphosphonates for Osteoporosis Treatment in Postmenopausal Women in Japan: A Retrospective Study Using Claims Data. Kosaka Y; Sugiyama T; Hara K; Kobayashi Y Tohoku J Exp Med; 2021 Oct; 255(2):147-155. PubMed ID: 34690222 [TBL] [Abstract][Full Text] [Related]
38. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. McHorney CA; Schousboe JT; Cline RR; Weiss TW Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
40. [Postmenopausal osteoporosis. Bisphosphonates are not all equal]. MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]